Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 3Multiple Myeloma 3Unspecified Adult Solid Tumor, Protocol Specific 2Solid Tumor 2Neoplasms 2Melanoma 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Refractory or Relapsed Solid Tumors 1Recurrence 1Prostatic Neoplasms 1Neoplasms, Plasma Cell 1Malignant Solid Tumour 1Lymphangioleiomyomatosis 1Leukemia, Myeloid, Acute 1Leukemia 1Gastrointestinal Neoplasms 1Estrogen Receptor Positive Breast Cancer 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Bone Metastases 1Adult Solid Neoplasm 1

Interventions

temsirolimus 2Sirolimus 2Gemcitabine 2ARQ 197 2veliparib 1sargramostim 1pegfilgrastim 1ixabepilone 1cixutumumab 1belinostat 1Vorinostat 1Topotecan 1Tolbutamide 1Taxes 1Sunitinib 1Rifampin 1Paclitaxel 1Omeprazole 1Midazolam 1Ketoconazole 1Isotretinoin 1Irinotecan 1Introns 1Interferon alpha-2 1Hydroxychloroquine 1Erlotinib Hydrochloride 1Epothilones 1Dextromethorphan 1Colony-Stimulating Factors 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Adult Solid Neoplasm × Hydroxychloroquine × Clear all
NCT00813423 2023-08-02

Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy

National Cancer Institute (NCI)

Phase 1 Completed
40 enrolled

Adult Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡